<p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）在周六发布的一份报告中被华尔街 Zen 的股票研究人员从 “强力买入” 评级下调至 “买入” 评级。</p>
<p>获取 <strong>Globus Medical</strong> 警报：</p>
<p>其他一些研究分析师也对 GMED 发表了评论。加拿大皇家银行在周五的一份研究报告中将 Globus Medical 的目标价格从 115.00 美元上调至 120.00 美元，并给予该公司 “跑赢大盘” 的评级。Weiss Ratings 在 4 月 15 日（星期三）的一份研究报告中重申了对 Globus Medical 股票的 “持有（c+）” 评级。Needham &amp; Company LLC 在周五的一份研究报告中将 Globus Medical 的目标价格从 114.00 美元上调至 117.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 2 月 25 日（星期三）的一份研究报告中设定了 Globus Medical 的目标价格为 115.00 美元。最后，Zacks Research 在 3 月 3 日（星期二）的一份研究报告中将 Globus Medical 的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 106.36 美元。</p>
<p><strong>获取我们最新的 GMED 研究报告</strong></p>
<h2>Globus Medical 股票表现</h2>
<p>GMED 的股票在周五开盘价为 77.81 美元。该公司的市值为 105.2 亿美元，市盈率为 18.10，PEG 比率为 1.99，贝塔值为 1.00。该公司的 50 日移动平均价格为 89.86 美元，200 日移动平均价格为 86.65 美元。Globus Medical 的 52 周低点为 51.79 美元，52 周高点为 101.40 美元。</p>
<p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）最近在 5 月 7 日（星期四）公布了季度财报。这家医疗设备公司报告本季度每股收益为 1.12 美元，超出分析师共识预期的 0.92 美元，超出幅度为 0.20 美元。该公司的季度收入为 7.5985 亿美元，而分析师预期为 7.4035 亿美元。Globus Medical 的股本回报率为 13.69%，净利润率为 18.92%。该公司的季度收入同比增长 27.0%。去年同期，该公司每股收益为 0.68 美元。Globus Medical 已将其 2026 财年的指导目标设定为每股收益 4.700-4.800 美元。整体来看，研究分析师预测 Globus Medical 在当前年度将发布每股收益 4.46 美元。</p>
<h2>内部活动</h2>
<p>在其他新闻中，执行副总裁 Kelly Huller 在 2 月 25 日（星期三）出售了该公司 20,000 股股票。该股票的平均售价为 94.50 美元，总价值为 1,890,000.00 美元。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。18.38% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家对冲基金和其他机构投资者最近对 GMED 的持仓进行了调整。Invesco Ltd.在第四季度将其在 Globus Medical 的持仓增加了 1,235.2%。Invesco Ltd.目前拥有 3,886,405 股该医疗设备公司的股票，价值 339,322,000 美元，此前在上个季度购买了额外的 3,595,339 股。蒙特利尔银行在第四季度将其在 Globus Medical 的持仓增加了 15,317.1%。蒙特利尔银行目前拥有 3,373,260 股该医疗设备公司的股票，价值 294,519,000 美元，此前在上个季度购买了额外的 3,351,380 股。Alliancebernstein L.P.在第三季度将其在 Globus Medical 的持仓增加了 1,303.9%。Alliancebernstein L.P.目前拥有 2,055,183 股该医疗设备公司的股票，价值 117,700,000 美元，此前在上个季度购买了额外的 1,908,795 股。Fuller &amp; Thaler Asset Management Inc.在第四季度购买了 Globus Medical 的新头寸，价值 90,411,000 美元。最后，挪威银行在第四季度购买了 Globus Medical 的新头寸，价值 89,922,000 美元。目前 95.16% 的股票由机构投资者持有。</p>
<h2>Globus Medical 新闻汇总</h2>
<p>以下是本周影响 Globus Medical 的主要新闻：</p>
<ul>
<li>积极情绪：Globus Medical 在第一季度的业绩和收入均超出预期，报告每股收益 1.12 美元，预期为 0.92 美元，销售额为 7.599 亿美元，预期为 7.404 亿美元；收入同比增长 27%，利润率改善。文章标题</li>
<li>积极情绪：该公司还将 2026 财年的每股收益指导上调至 4.70-4.80 美元，高于共识，显示管理层对持续增长的信心。文章标题</li>
<li>积极情绪：加拿大皇家银行将 GMED 的目标价格从 115 美元上调至 120 美元，并维持 “跑赢大盘” 评级，而 Needham 将目标价格从 114 美元上调至 117 美元，并重申 “买入” 评级，反映出分析师的乐观情绪。文章标题</li>
<li>中性情绪：投资者也在消化该公司的第一季度财报电话会议记录及相关的财报后报道，主要强调强劲的业绩，而不是增加新的催化剂。文章标题</li>
<li>消极情绪：尽管业绩超出预期且指导上调，但股票仍然下跌，交易者似乎在获利了结，并关注在报告发布前已经提升的预期。文章标题</li>
</ul>
<h2>关于 Globus Medical</h2>
<p>（获取免费报告）</p>
<p>Globus Medical, Inc（纽约证券交易所代码：GMED）是一家领先的医疗设备公司，专注于脊柱和骨科应用的肌肉骨骼解决方案。该公司成立于 2003 年，由 David C. Paul 创立，总部位于宾夕法尼亚州 Audubon，开发、制造和销售旨在治疗脊柱疾病和促进骨愈合的植入设备和外科器械。其产品组合涵盖了用于微创和开放手术的解决方案，包括椎间融合设备、椎弓根螺钉系统和用于增强融合效果的生物制剂。</p>
<p>除了其核心脊柱业务外，Globus Medical 还扩展到了机器人和导航系统，以支持手术室的精确性和效率。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Globus Medical 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
<p>在考虑 Globus Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Globus Medical 并不在名单上。</p>
<p>虽然 Globus Medical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Globus医疗

<p>华尔街禅将 Globus Medical（NYSE:GMED）的评级从 “强力买入” 下调至 “买入”。其他分析师的看法不一，加拿大皇家银行将其目标价上调至 120 美元，Needham 则上调至 117 美元，均维持积极评级。该股开盘价为 77.81 美元，市值为 105.2 亿美元。Globus Medical 报告了强劲的第一季度业绩，EPS 为 1.12 美元，营收为 7.5985 亿美元，较去年同期增长 27%。公司还将 2026 财年的 EPS 指引上调至 4.70-4.80 美元，显示出增长信心</p>

<p>Globus Medical (NYSE:GMED - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）在周六发布的一份报告中被华尔街 Zen 的股票研究人员从 “强力买入” 评级下调至 “买入” 评级。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Globus Medical</strong> 警报：</p>
</div><p>A number of other research analysts have also commented on GMED. Royal Bank Of Canada increased their price objective on Globus Medical from $115.00 to $120.00 and gave the company an &#34;outperform&#34; rating in a research report on Friday. Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Globus Medical in a research report on Wednesday, April 15th. Needham &amp; Company LLC increased their price objective on Globus Medical from $114.00 to $117.00 and gave the company a &#34;buy&#34; rating in a research report on Friday. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded Globus Medical from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $106.36.</p>
<div class="lb-trans"><p>其他一些研究分析师也对 GMED 发表了评论。加拿大皇家银行在周五的一份研究报告中将 Globus Medical 的目标价格从 115.00 美元上调至 120.00 美元，并给予该公司 “跑赢大盘” 的评级。Weiss Ratings 在 4 月 15 日（星期三）的一份研究报告中重申了对 Globus Medical 股票的 “持有（c+）” 评级。Needham &amp; Company LLC 在周五的一份研究报告中将 Globus Medical 的目标价格从 114.00 美元上调至 117.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 2 月 25 日（星期三）的一份研究报告中设定了 Globus Medical 的目标价格为 115.00 美元。最后，Zacks Research 在 3 月 3 日（星期二）的一份研究报告中将 Globus Medical 的评级从 “持有” 上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，九位分析师给予 “买入” 评级，五位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 106.36 美元。</p>
</div><p><strong>Get Our Latest Research Report on GMED</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 GMED 研究报告</strong></p>
</div><h2>Globus Medical Stock Performance</h2>
<div class="lb-trans"><h2>Globus Medical 股票表现</h2>
</div><p>Shares of GMED opened at $77.81 on Friday. The firm has a market capitalization of $10.52 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 1.99 and a beta of 1.00. The business's fifty day moving average price is $89.86 and its two-hundred day moving average price is $86.65. Globus Medical has a 52 week low of $51.79 and a 52 week high of $101.40.</p>
<div class="lb-trans"><p>GMED 的股票在周五开盘价为 77.81 美元。该公司的市值为 105.2 亿美元，市盈率为 18.10，PEG 比率为 1.99，贝塔值为 1.00。该公司的 50 日移动平均价格为 89.86 美元，200 日移动平均价格为 86.65 美元。Globus Medical 的 52 周低点为 51.79 美元，52 周高点为 101.40 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.69% and a net margin of 18.92%.The business's quarterly revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, research analysts forecast that Globus Medical will post 4.46 EPS for the current year.</p>
<div class="lb-trans"><p>Globus Medical（纽约证券交易所代码：GMED - 获取免费报告）最近在 5 月 7 日（星期四）公布了季度财报。这家医疗设备公司报告本季度每股收益为 1.12 美元，超出分析师共识预期的 0.92 美元，超出幅度为 0.20 美元。该公司的季度收入为 7.5985 亿美元，而分析师预期为 7.4035 亿美元。Globus Medical 的股本回报率为 13.69%，净利润率为 18.92%。该公司的季度收入同比增长 27.0%。去年同期，该公司每股收益为 0.68 美元。Globus Medical 已将其 2026 财年的指导目标设定为每股收益 4.700-4.800 美元。整体来看，研究分析师预测 Globus Medical 在当前年度将发布每股收益 4.46 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Kelly Huller sold 20,000 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 18.38% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Kelly Huller 在 2 月 25 日（星期三）出售了该公司 20,000 股股票。该股票的平均售价为 94.50 美元，总价值为 1,890,000.00 美元。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。18.38% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in GMED. Invesco Ltd. boosted its position in shares of Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock worth $339,322,000 after purchasing an additional 3,595,339 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock worth $294,519,000 after purchasing an additional 3,351,380 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company's stock worth $117,700,000 after purchasing an additional 1,908,795 shares during the last quarter. Fuller &amp; Thaler Asset Management Inc. bought a new position in shares of Globus Medical in the 4th quarter worth $90,411,000. Finally, Norges Bank bought a new position in shares of Globus Medical in the 4th quarter worth $89,922,000. 95.16% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 GMED 的持仓进行了调整。Invesco Ltd.在第四季度将其在 Globus Medical 的持仓增加了 1,235.2%。Invesco Ltd.目前拥有 3,886,405 股该医疗设备公司的股票，价值 339,322,000 美元，此前在上个季度购买了额外的 3,595,339 股。蒙特利尔银行在第四季度将其在 Globus Medical 的持仓增加了 15,317.1%。蒙特利尔银行目前拥有 3,373,260 股该医疗设备公司的股票，价值 294,519,000 美元，此前在上个季度购买了额外的 3,351,380 股。Alliancebernstein L.P.在第三季度将其在 Globus Medical 的持仓增加了 1,303.9%。Alliancebernstein L.P.目前拥有 2,055,183 股该医疗设备公司的股票，价值 117,700,000 美元，此前在上个季度购买了额外的 1,908,795 股。Fuller &amp; Thaler Asset Management Inc.在第四季度购买了 Globus Medical 的新头寸，价值 90,411,000 美元。最后，挪威银行在第四季度购买了 Globus Medical 的新头寸，价值 89,922,000 美元。目前 95.16% 的股票由机构投资者持有。</p>
</div><h2>Globus Medical News Roundup</h2>
<div class="lb-trans"><h2>Globus Medical 新闻汇总</h2>
</div><p>Here are the key news stories impacting Globus Medical this week:</p>
<div class="lb-trans"><p>以下是本周影响 Globus Medical 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title</li>
<li>Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title</li>
<li>Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title</li>
<li>Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title</li>
<li>Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Globus Medical 在第一季度的业绩和收入均超出预期，报告每股收益 1.12 美元，预期为 0.92 美元，销售额为 7.599 亿美元，预期为 7.404 亿美元；收入同比增长 27%，利润率改善。文章标题</li>
<li>积极情绪：该公司还将 2026 财年的每股收益指导上调至 4.70-4.80 美元，高于共识，显示管理层对持续增长的信心。文章标题</li>
<li>积极情绪：加拿大皇家银行将 GMED 的目标价格从 115 美元上调至 120 美元，并维持 “跑赢大盘” 评级，而 Needham 将目标价格从 114 美元上调至 117 美元，并重申 “买入” 评级，反映出分析师的乐观情绪。文章标题</li>
<li>中性情绪：投资者也在消化该公司的第一季度财报电话会议记录及相关的财报后报道，主要强调强劲的业绩，而不是增加新的催化剂。文章标题</li>
<li>消极情绪：尽管业绩超出预期且指导上调，但股票仍然下跌，交易者似乎在获利了结，并关注在报告发布前已经提升的预期。文章标题</li>
</ul>
</div><h2>About Globus Medical</h2>
<div class="lb-trans"><h2>关于 Globus Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.</p>
<div class="lb-trans"><p>Globus Medical, Inc（纽约证券交易所代码：GMED）是一家领先的医疗设备公司，专注于脊柱和骨科应用的肌肉骨骼解决方案。该公司成立于 2003 年，由 David C. Paul 创立，总部位于宾夕法尼亚州 Audubon，开发、制造和销售旨在治疗脊柱疾病和促进骨愈合的植入设备和外科器械。其产品组合涵盖了用于微创和开放手术的解决方案，包括椎间融合设备、椎弓根螺钉系统和用于增强融合效果的生物制剂。</p>
</div><p>In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.</p>
<div class="lb-trans"><p>除了其核心脊柱业务外，Globus Medical 还扩展到了机器人和导航系统，以支持手术室的精确性和效率。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Globus Medical 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Globus Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Globus Medical 并不在名单上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Globus Medical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Globus Medical (NYSE:GMED) Stock Rating Lowered by Wall Street Zen

Market Beat

Globus Medical（纽约证券交易所代码：GMED）的股票评级被 Wall Street Zen 下调